• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Mar 1987; 79(3): 918–925.
PMCID: PMC424237

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.

Abstract

Gram-negative septicemia elicits multiple abnormalities of the coagulation system. Although products of coagulation can lead to clot formation, thereby potentiating organ damage, recent work has shown that low concentrations of thrombin can protect animals from the shock state. Because these amounts of thrombin also lead to formation in vivo of the anticoagulant enzyme, activated protein C, we examined the role of protein C in modulation of Escherichia coli shock in baboons. First, we infused activated protein C and lethal concentrations of E. coli organisms, which prevented the coagulopathic, hepatotoxic, and lethal effects of E. coli. Second, using an antibody to protein C we blocked protein C activation in vivo to determine if this influenced the response to lethal and sublethal concentrations of E. coli organisms. Under these conditions the response to lethal concentrations of E. coli organisms was made more severe and the response to sublethal concentrations of E. coli was made lethal. The coagulopathic, hepatotoxic, and lethal responses in this latter case were prevented by infusion of exogenous protein C.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Taylor FB, Jr, Chang A, Hinshaw LB, Esmon CT, Archer LT, Beller BK. A model for thrombin protection against endotoxin. Thromb Res. 1984 Oct 15;36(2):177–185. [PubMed]
  • Comp PC, Jacocks RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. J Clin Invest. 1982 Jul;70(1):127–134. [PMC free article] [PubMed]
  • Wetmore R, Gurewich V. The role of fibrin monomer and an in vivo thrombin-induced-anticoagulant in experimental venous thrombosis. Scand J Haematol. 1974;12(3):204–212. [PubMed]
  • Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest. 1981 Nov;68(5):1221–1228. [PMC free article] [PubMed]
  • Kisiel W, Ericsson LH, Davie EW. Proteolytic activation of protein C from bovine plasma. Biochemistry. 1976 Nov 2;15(22):4893–4900. [PubMed]
  • Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta. 1979 Dec 7;571(2):333–342. [PubMed]
  • Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry. 1980 Feb 5;19(3):401–410. [PubMed]
  • Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 1982 May;59(5):1067–1072. [PubMed]
  • Rodeghiero F, Mannucci PM, Viganò S, Barbui T, Gugliotta L, Cortellaro M, Dini E. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood. 1984 Apr;63(4):965–969. [PubMed]
  • Taylor FB, Jr, Lockhart MS. Whole blood clot lysis: in vitro modulation by activated protein C. Thromb Res. 1985 Mar 15;37(6):639–649. [PubMed]
  • WROBLEWSKI F, LADUE JS. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med. 1956 Apr;91(4):569–571. [PubMed]
  • Hinshaw LB, Brackett DJ, Archer LT, Beller BK, Wilson MF. Detection of the 'hyperdynamic state' of sepsis in the baboon during lethal E. coli infusion. J Trauma. 1983 May;23(5):361–365. [PubMed]
  • Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest. 1986 Feb;77(2):416–425. [PMC free article] [PubMed]
  • Coalson JJ, Benjamin BA, Archer LT, Beller BK, Spaet RH, Hinshaw LB. A pathologic study of Escherichia coli shock in the baboon and the response to adrenocorticosteroid treatment. Surg Gynecol Obstet. 1978 Nov;147(5):726–736. [PubMed]
  • Mannucci PM, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet. 1982 Aug 28;2(8296):463–467. [PubMed]
  • Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ. Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood. 1982 Jul;60(1):261–264. [PubMed]
  • Rodeghiero F, Mannucci PM, Viganò S, Barbui T, Gugliotta L, Cortellaro M, Dini E. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood. 1984 Apr;63(4):965–969. [PubMed]
  • Harris KW, Esmon CT. Protein S is required for bovine platelets to support activated protein C binding and activity. J Biol Chem. 1985 Feb 25;260(4):2007–2010. [PubMed]
  • Stern DM, Nawroth PP, Harris K, Esmon CT. Cultured bovine aortic endothelial cells promote activated protein C-protein S-mediated inactivation of factor Va. J Biol Chem. 1986 Jan 15;261(2):713–718. [PubMed]
  • Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2249–2252. [PMC free article] [PubMed]
  • Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 1982 May;59(5):1067–1072. [PubMed]
  • Nesheim ME, Canfield WM, Kisiel W, Mann KG. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem. 1982 Feb 10;257(3):1443–1447. [PubMed]
  • Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacob HS. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest. 1978 May;61(5):1161–1167. [PMC free article] [PubMed]
  • Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. [PubMed]
  • Gajdusek C, Carbon S, Ross R, Nawroth P, Stern D. Activation of coagulation releases endothelial cell mitogens. J Cell Biol. 1986 Aug;103(2):419–428. [PMC free article] [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

Formats:

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...